| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-14 | New Oncology (Germany) Gustave Roussy Cancer Campus (France) | diagnostic platform ‘NEO’ | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2014-10-14 | Philips (The Netherlands) Dutch Radboud university medical center (The Netherlands) | wearable diagnostic prototype | chronic obstructive pulmonary disease (COPD) | collaboration |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Collaboration agreement |
| 2014-10-14 | BioSilta (UK) Sigma-Aldrich (USA - MO) | EnPresso® growth systems for microbial cell cultures | distribution |
Technology - Services | Distribution agreement | |
| 2014-10-13 | Eisai (Japan) Hikma Pharmaceuticals | Fycompa® (perampanel) | adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older | distribution |
CNS diseases - Neurological diseases | Distribution agreement |
| 2014-10-13 | Stada (Germany) Richter-Helm BioTec GmbH & Co (Germany) | teriparatide (biosimilar version of Forsteo®) | licensing |
Licensing agreement | ||
| 2014-10-13 | MRC Technology (UK) Proximagen (UK) | Macrophage migration inhibitory factor (MIF) inhibitors | inflammatory and autoimmune disease | collaboration |
Autoimmune diseases – Inflammatory diseases | Collaboration agreement |
| 2014-10-13 | BMS (USA - NY) Janssen Research & Development - J&J (USA - NJ) Pharmacyclics (USA - CA) | Opdivo® (nivolumab) and Imbruvica® (ibrutinib) | non-Hodgkin Lymphoma | Cancer - Oncology | Clinical research agreement | |
| 2014-10-13 | Cellectis (France) Oncodesign (France) | preclinical studies of drug candidates of drug candidates from UCART (for Universal Chimeric Antigen Receptor – T cells) portfolio | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-10-10 | Oxford BioMedica (UK) Novartis (Switzerland) | clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology | production |
Cancer - Oncology | Production agreement | |
| 2014-10-10 | Ipsen (France) | chief financial officer | nomination | Nomination | ||
| 2014-10-09 | Vernalis (UK) RedoxTherapies (USA - MA) | vipadenant (V2006) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2014-10-09 | Transgene (France) | nomination | Nomination | |||
| 2014-10-09 | Roche (Switzerland) AbVitro (USA - CA) | primer extension based target enrichment (PETE) technology | licensing |
Technology - Services | Licensing agreement | |
| 2014-10-09 | Oryzon Genomics (Spain) | establishment of a new subsidiary in the US |
Cancer - Oncology - Neurodegenerative diseases | Establishment of a new subsidiary in the US | ||
| 2014-10-08 | Nanobiotix (France) PharmaEngine (Taïwan) | NBTXR3 | prostate cancer, colorectal cancer, hepatocarcinoma, soft tissue sarcoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-10-08 | CSL (Australia) | extension of a production plant |
Construction of a production plant | |||
| 2014-10-08 | Medimmune (USA - global biologics arm of AstraZeneca (UK), Shionogi (Japan) | Shionogi’s cardiovascular biologic program | acute coronary syndrome | licensing |
Cardiovascular diseases | Licensing agreement |
| 2014-10-08 | Bayer (Germany) | member of the supervisory board | nomination | Nomination | ||
| 2014-10-08 | Ubiquigent (UK) University of Dundee (UK) | new ubiquitin system targeted compound libraries | development commercialisation |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Neurological diseases - Infections diseases - Immunological diseases | Development agreement | |
| 2014-10-08 | Dilafor (Sweden) Opocrin (Italy) | tafoxiparin | obstetrical indications | manufacturing production |
Women health | Production agreement |
